MCID: BRC012
MIFTS: 66

Brucellosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Brucellosis

MalaCards integrated aliases for Brucellosis:

Name: Brucellosis 12 76 53 59 55 3 44 15 73
Undulant Fever 12 53 3
Mediterranean Fever 12 76
Gibraltar Fever 12 53
Malta Fever 12 53
Bang's Disease 12
Maltese Fever 12
Cyprus Fever 53
Rock Fever 53

Characteristics:

Orphanet epidemiological data:

59
brucellosis
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11077
ICD9CM 35 023 023.9
MeSH 44 D002006
NCIt 50 C84602
SNOMED-CT 68 75702008
Orphanet 59 ORPHA1304
ICD10 via Orphanet 34 A23.3 A23.8 A23.9 more
UMLS via Orphanet 74 C0006309
MESH via Orphanet 45 D002006
UMLS 73 C0006309

Summaries for Brucellosis

NIH Rare Diseases : 53 Brucellosis is a bacterial infection that spreads from animals to people via unpasteurized dairy products or by exposure to contaminated animal products or infected animals. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs. Brucellosis can cause of range of signs and symptoms, some of which may persist or recur. Initial symptoms may include fever, sweats, malaise, anorexia, headache, fatigue, and/or pain in the muscles, joints, and/or back. Symptoms that may persist or recur include fevers, arthritis, swelling of the testicle and scrotum, swelling of the heart (endocarditis), neurologic symptoms (in up to 5% of cases), chronic fatigue, depression, and/or swelling of the liver or spleen. People who are in jobs or settings that increase exposure to the bacteria are at increased risk for infection. Antibiotics are used to treat brucellosis. Recovery may take a few weeks to several months, and relapses are common. Death from brucellosis is rare, occurring in no more than 2% of cases.

MalaCards based summary : Brucellosis, also known as undulant fever, is related to familial mediterranean fever and amyloidosis aa, and has symptoms including fever, fatigue and back pain. An important gene associated with Brucellosis is MEFV (MEFV, Pyrin Innate Immunity Regulator), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has symptom fever, has symptom sweat, has symptom headache, has symptom back pain, has symptom physical weakness, has symptom joint pain and has symptom fatigue.

Wikipedia : 76 Brucellosis is a highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked... more...

Related Diseases for Brucellosis

Diseases related to Brucellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 642)
# Related Disease Score Top Affiliating Genes
1 familial mediterranean fever 33.9 CRP IL1RN MEFV SAA1 TNF
2 amyloidosis aa 32.0 CRP MEFV SAA1
3 polyarteritis nodosa 30.6 CRP IL6 MEFV
4 crohn's disease 30.5 TNF SLC11A1 IL10 CRP
5 q fever 30.4 IFNG IL10 IL4 IL6 TLR4 TNF
6 celiac disease 1 30.4 TNF IL2 IL10 IFNG
7 spondyloarthropathy 30.4 IFNG IL10 IL4 IL6 TNF
8 purpura 30.4 CRP IL6 TNF
9 endocarditis 30.2 CRP CXCL8 IL10 IL6 TNF
10 spondylitis 30.2 CRP IL1RN IL6 TNF
11 leptospirosis 30.2 CRP CXCL8 IFNG IL10 IL6 TNF
12 proliferative glomerulonephritis 30.2 IFNG IL4 IL6
13 relapsing polychondritis 30.2 CRP IFNG IL6
14 extrapulmonary tuberculosis 30.2 IFNG IL10 SLC11A1
15 cryopyrin-associated periodic syndrome 30.1 CRP IL1RN IL6
16 fatty liver disease 30.1 CXCL8 IL6 TNF
17 hyper-igd syndrome 30.1 CRP IL1RN SAA1
18 rheumatic heart disease 30.1 IL10 IL4 IL6 TNF
19 appendicitis 30.1 CRP CXCL8 IL10 IL6 TNF
20 multiple sclerosis 30.1 IFNG IL10 IL2 IL2RA IL4 IL6
21 drug reaction with eosinophilia and systemic symptoms 30.0 CRP TNF
22 campylobacteriosis 30.0 IFNG SLC11A1 TLR4
23 scleritis 30.0 IFNG IL4 TNF
24 heart disease 30.0 CRP CXCL8 IL10 IL6 TNF
25 crohn's colitis 30.0 CXCL8 IFNG IL2 TNF
26 relapsing fever 29.9 CRP MEFV TNF
27 ischemic heart disease 29.9 TNF IL6 CRP
28 aseptic meningitis 29.9 TNF IL1RN IL10 IFNG CXCL8
29 capillary leak syndrome 29.9 CXCL8 IL2 IL6
30 reactive arthritis 29.9 CRP IFNG IL10 TNF
31 ileitis 29.9 IL6 TLR4 TNF
32 end stage renal failure 29.9 CRP IL6 TNF
33 arteries, anomalies of 29.9 CRP IL6 TNF
34 meningitis 29.9 TNF IL6 IL10 IFNG CXCL8 CRP
35 acute respiratory distress syndrome 29.9 CXCL8 IL6 TNF
36 central nervous system vasculitis 29.9 CRP IFNG IL6 TNF
37 tuberculous peritonitis 29.8 CRP IFNG TNF
38 hepatitis a 29.8 IFNG IL10 TNF
39 neuritis 29.8 IFNG IL4 TNF
40 rheumatic fever 29.8 IL10 IL2 IL6 TNF
41 echinococcosis 29.8 IFNG IL10 IL6 TLR4 TNF
42 infective endocarditis 29.8 CRP IL6 TNF
43 nonalcoholic fatty liver disease 29.8 CRP IL6 TNF
44 spondyloarthropathy 1 29.7 CRP TLR4 TNF
45 toxoplasmosis 29.7 CD40LG IFNG IL10 IL4 IL6 TLR4
46 vasculitis 29.7 CD40LG CRP MEFV TNF
47 periodontitis 29.7 TNF TLR4 IL6 IL4 IL10 IFNG
48 pertussis 29.7 IL10 IL6 TLR4 TNF
49 septic arthritis 29.7 TLR4 CXCL8 CRP
50 colitis 29.7 CXCL8 IFNG IL10 IL2 IL4 IL6

Graphical network of the top 20 diseases related to Brucellosis:



Diseases related to Brucellosis

Symptoms & Phenotypes for Brucellosis

Symptoms:

12
  • fever
  • fatigue
  • back pain
  • headache
  • joint pain
  • sweat
  • physical weakness

GenomeRNAi Phenotypes related to Brucellosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CD40LG CXCL8 IL10 IL18 IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CD40LG CXCL8 IL10 IL18 IL2 IL2RA

MGI Mouse Phenotypes related to Brucellosis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 CD40LG CRP IFNG IL10 IL18 IL1RN
2 hematopoietic system MP:0005397 10.31 CD40LG IFNG IL10 IL18 IL1RN IL2
3 immune system MP:0005387 10.3 CD40LG CRP IFNG IL10 IL18 IL1RN
4 cellular MP:0005384 10.29 CD40LG IFNG IL10 IL18 IL1RN IL2
5 cardiovascular system MP:0005385 10.26 CD40LG CRP IFNG IL10 IL18 IL1RN
6 growth/size/body region MP:0005378 10.25 IFNG IL10 IL18 IL1RN IL2 IL2RA
7 digestive/alimentary MP:0005381 10.24 IFNG IL10 IL18 IL2 IL2RA IL4
8 mortality/aging MP:0010768 10.18 CD40LG IFNG IL10 IL18 IL1RN IL2
9 endocrine/exocrine gland MP:0005379 10.13 CD40LG IFNG IL10 IL2 IL2RA IL4
10 integument MP:0010771 10.13 CD40LG IFNG IL10 IL18 IL1RN IL4
11 liver/biliary system MP:0005370 10.01 IFNG IL10 IL2 IL4 IL6 MEFV
12 reproductive system MP:0005389 9.96 CD40LG IFNG IL10 IL1RN IL2 IL4
13 neoplasm MP:0002006 9.87 IFNG IL10 IL2 IL6 SLC11A1 TLR4
14 respiratory system MP:0005388 9.76 IFNG IL10 IL2 IL2RA IL4 IL6
15 skeleton MP:0005390 9.61 CD40LG IFNG IL10 IL1RN IL4 IL6
16 vision/eye MP:0005391 9.28 IFNG IL10 IL18 IL2 IL2RA IL4

Drugs & Therapeutics for Brucellosis

Drugs for Brucellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 812)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
3
Abatacept Approved Phase 4 332348-12-6 10237
4
Atenolol Approved Phase 4,Not Applicable 29122-68-7 2249
5
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
6
Naloxone Approved, Vet_approved Phase 4,Not Applicable 465-65-6 5284596
7
Tocopherol Approved, Investigational Phase 4,Phase 2,Phase 3 1406-66-2 14986
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
10
Cobicistat Approved Phase 4 1004316-88-4
11
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-86-8 6167 2833
12
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 58-61-7 60961
13
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
14
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
15
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
16 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3 376348-65-1 3002977
18
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
19
Telavancin Approved Phase 4 372151-71-8
20
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
21
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
22
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
23
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
24
Regadenoson Approved, Investigational Phase 4,Not Applicable 313348-27-5 219024
25
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
26
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
27
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
28
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
29
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
30
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
31
Donepezil Approved Phase 4 120014-06-4 3152
32
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
33
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
34
Memantine Approved, Investigational Phase 4 19982-08-2 4054
35
Febuxostat Approved Phase 4,Phase 2 144060-53-7 134018
36 Nutmeg Approved Phase 4
37
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
38
Artesunate Approved, Investigational Phase 4,Phase 3 88495-63-0 5464098 6917864
39
Amodiaquine Approved, Investigational Phase 4,Phase 3 86-42-0 2165
40
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
41
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
42
Dapsone Approved, Investigational Phase 4 80-08-0 2955
43
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
44
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
45
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 1302 156391
46
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
47
Ramipril Approved Phase 4 87333-19-5 5362129
48
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
49
Insulin Aspart Approved Phase 4,Phase 2 116094-23-6 16132418
50
Testosterone Approved, Investigational Phase 4,Phase 3,Not Applicable 58-22-0 6013

Interventional clinical trials:

(show top 50) (show all 1034)
# Name Status NCT ID Phase Drugs
1 VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department Unknown status NCT00468065 Phase 4
2 Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression Unknown status NCT01875224 Phase 4 Belatacept;Tacrolimus
3 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
4 Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers Unknown status NCT01492140 Phase 4
5 Nasal Naloxone for Narcotic Overdose Unknown status NCT01912573 Phase 4 Intranasal (IN) naloxone;Intravenous (IV) naloxone;Intramuscular (IM) naloxone;Intraosseus (IO) naloxone
6 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
7 A Prospective Study of the InterFuse T(tm), Unknown status NCT02678130 Phase 4
8 Sleep and Cognition After Atripla to Stribild Switch Unknown status NCT02283060 Phase 4 Stribild;Atripla
9 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
10 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed NCT01449006 Phase 4 Maraviroc
11 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) Completed NCT00663403 Phase 4 Daptomycin
12 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed NCT02392208 Phase 4 Telavancin
13 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation Completed NCT00578968 Phase 4 Tiotropium;Placebo
14 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4 Ranolazine
15 Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD) Completed NCT01048879 Phase 4
16 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis Completed NCT00877370 Phase 4 ertapenem
17 The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems Completed NCT00988117 Phase 4 Rivastigmine Patch 9.5 cm2
18 Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET Completed NCT01109992 Phase 4 Exercise plus Regadenoson (Lexercise);Regadenoson (Lexiscan)
19 Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
20 Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS) Completed NCT00263393 Phase 4 ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
21 Helping Those With Mental Illness Quit Smoking Completed NCT01783912 Phase 4 Nicotine Patch
22 Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures Completed NCT01376960 Phase 4
23 ULTRA Study for Pacemaker Patients Completed NCT00133289 Phase 4
24 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed NCT00224289 Phase 4 Latanoprost 0.005%
25 Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas Completed NCT00295178 Phase 4 Daptomycin;Vancomycin
26 Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer Completed NCT00950053 Phase 4
27 Needle Length In Obese Insulin-Using Diabetic Subjects Completed NCT00541372 Phase 4
28 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed NCT00177671 Phase 4 Escitalopram;Donepezil;Venlafaxine;Placebo;Duloxetine
29 World-wide Randomized Antibiotic Envelope Infection Prevention Trial Completed NCT02277990 Phase 4
30 Foot and Ankle Clinic Application for Liposomal Related Anesthetic Completed NCT02586077 Phase 4 Exparel
31 Comparative Performance of PureVision, Acuvue Oasys and O2Optix Completed NCT00640341 Phase 4
32 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
33 Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia Completed NCT01844102 Phase 4
34 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed NCT01763996 Phase 4 Febuxostat;Febuxostat placebo
35 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed NCT02019264 Phase 4 APD356-Lorcaserin hydrochloride;Placebo
36 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
37 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
38 Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression Completed NCT00531947 Phase 4 Selegiline Transdermal System;Placebo
39 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
40 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
41 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4 celecoxib;Ibuprofen;Naproxen
42 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. Completed NCT00153101 Phase 4 Telmisartan;Combination of Telmisartan and Ramipril;Ramipril
43 Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy Recruiting NCT03554486 Phase 4 Fiasp;Novolog
44 CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera Recruiting NCT03705585 Phase 4 Vivotif Typhoid Oral Vaccine;Vaxchora
45 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Recruiting NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
46 Randomised Evaluation of Sodium Dialysate Levels on Vascular Events Recruiting NCT02823821 Phase 4
47 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
48 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
49 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure Recruiting NCT02787044 Phase 4
50 Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study Recruiting NCT02202369 Phase 4

Search NIH Clinical Center for Brucellosis

Cochrane evidence based reviews: brucellosis

Genetic Tests for Brucellosis

Anatomical Context for Brucellosis

MalaCards organs/tissues related to Brucellosis:

41
Testes, Liver, Heart, Spleen, T Cells, Lung, Prostate

Publications for Brucellosis

Articles related to Brucellosis:

(show top 50) (show all 1395)
# Title Authors Year
1
Brucellosis seroprevalence in dairy cattle in China during 2008-2018: A systematic review and meta-analysis. ( 30308207 )
2019
2
Knowledge, attitudes, and practices (KAP) related to brucellosis and factors affecting knowledge sharing on animal diseases: a cross-sectional survey in the dry zone of Sri Lanka. ( 29392550 )
2018
3
First case of cervical epidural abscess caused by brucellosis in Saudi Arabia: A case report and literature review. ( 29682450 )
2018
4
Association between human brucellosis and adverse pregnancy outcome: a cross-sectional population-based study. ( 29344838 )
2018
5
Congenital Brucellosis: A Systematic Review of the Literature. ( 29957148 )
2018
6
Consequences of brucellosis infection during pregnancy: A systematic review of the literature. ( 29885371 )
2018
7
The microRNA expression signature of CD4+ T cells in the transition of brucellosis into chronicity. ( 29897958 )
2018
8
Rifampicin-Induced Fever in a Patient with Brucellosis: A Case Report. ( 29427095 )
2018
9
Trend Analysis and Affecting Components of Human Brucellosis Incidence During 2006 to 2016. ( 29416212 )
2018
10
Epidemiological, Clinical and Molecular Characterization of Human Brucellosis in Bosnia and Herzegovina - An Ongoing Brucellosis Outbreak. ( 29957971 )
2018
11
The detection of brucellosis antibody in whole serum based on the low-fouling electrochemical immunosensor fabricated with magnetic Fe<sub>3</sub>O<sub>4</sub>@Au@PEG@HA nanoparticles. ( 29894850 )
2018
12
Brucellosis after Cardiac Transplantation. ( 29932889 )
2018
13
Hematologic Manifestations of Brucellosis in Children. ( 29329166 )
2018
14
Liver involvement is associated with blood culture positivity and high agglutination titre in patients with brucellosis in Turkey. ( 29972349 )
2018
15
Serosurveillance of Coxiellosis (Q-fever) and Brucellosis in goats in selected provinces of Lao People's Democratic Republic. ( 29649313 )
2018
16
Rethinking &amp;quot;One Health&amp;quot; through Brucellosis: ethics, boundaries and politics. ( 29869782 )
2018
17
Myelitis and Polyradiculoneuropathy With Severe Pain: Unusual Neurological Manifestations as Presenting Symptoms of Brucellosis. ( 29953037 )
2018
18
Brucellosis Prevalence in Brazilian Slaughterhouses with Different Meat Inspection Systems. ( 29897272 )
2018
19
Spastic paraparesis and sensorineural hearing loss: keep brucellosis in mind. ( 29406895 )
2018
20
Seroprevalence of bovine brucellosis and associated risk factors in Nakasongola district, Uganda. ( 29948776 )
2018
21
First case-control study of zoonotic brucellosis in Gafsa district, Southwest Tunisia. ( 29911160 )
2018
22
Evaluation of three serological tests for diagnosis of bovine brucellosis in smallholder farms in Pakistan by estimating sensitivity and specificity using Bayesian latent class analysis. ( 29290297 )
2018
23
Prevalence of brucellosis among patients attending Wau Hospital, South Sudan. ( 29949605 )
2018
24
An autoimmune disease-associated risk variant in the<i>TNFAIP3</i>gene plays a protective role in brucellosis that is mediated by the NF-kappa B signaling pathway. ( 29343543 )
2018
25
Abortions in an organized dairy farm from North India reveal the possibility of breed susceptibility to Bovine Brucellosis. ( 29911159 )
2018
26
The sero-prevalence of brucellosis in cattle and their herders in Bahr el Ghazal region, South Sudan. ( 29924843 )
2018
27
Brucellosis Risk in Urban and Agro-pastoral Areas in Tanzania. ( 29344824 )
2018
28
Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action. ( 29325516 )
2018
29
Brucellosis in West and Central Africa: A review of the current situation in a changing landscape of dairy cattle systems. ( 29287761 )
2018
30
Serological study of brucellosis in Argentine Creole sheep. ( 29310845 )
2018
31
Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis. ( 29888294 )
2018
32
Prevalence and risk factors for brucellosis in prolonged fever patients in post-conflict Northern Uganda. ( 29977253 )
2018
33
Individual-based modelling and control of bovine brucellosis. ( 29892455 )
2018
34
Ontology-Based Meta-Analysis of Animal and Human Adverse Events Associated With Licensed Brucellosis Vaccines. ( 29867505 )
2018
35
Trends of reported human brucellosis cases in mainland China from 2007 to 2017: an exponential smoothing time series analysis. ( 29921215 )
2018
36
Acute liver failure complication of brucellosis infection: a case report and review of the literature. ( 29519244 )
2018
37
Seroreactivity and Risk Factors Associated with Human Brucellosis among Cattle Slaughterhouse Workers in South Korea. ( 30380642 )
2018
38
Association of Brucellosis with Abortion Prevalence in Humans and Animals in Africa: A Review. ( 30381939 )
2018
39
Cross-sectional study of brucellosis and Q fever in Thailand among livestock in two districts at the Thai-Cambodian border, Sa Kaeo province. ( 30386815 )
2018
40
Animal brucellosis control or eradication programs worldwide: A systematic review of experiences and lessons learned. ( 30388992 )
2018
41
Knowledge and perception of pastoral community members about brucellosis as a cause of abortion in animals and its zoonotic importance in Amibara district, Afar Region, Ethiopia. ( 30395605 )
2018
42
A study to identify the practices of the buffalo keepers which inadvertently lead to the spread of brucellosis in Delhi. ( 30400899 )
2018
43
Sero-prevalence and associated risk factors of Brucellosis among Malaria negative febrile out-patients in Wakiso district, Central Uganda. ( 30409158 )
2018
44
Predictors of therapeutic failure among patients with acute brucellosis treated by dual therapy with doxycycline-rifampin. ( 30411836 )
2018
45
Risk factors of brucellosis seropositivity in Bactrian camels of Mongolia. ( 30424746 )
2018
46
A Neglected Animal Model for a Neglected Disease: Guinea Pigs and the Search for an Improved Animal Model for Human Brucellosis. ( 30429834 )
2018
47
Successful resolution of Hemophagocytic lymphohistiocytosis associated to brucellosis in the adult. ( 30430494 )
2018
48
Serological and molecular analysis for brucellosis in selected swine herds from Southern India. ( 30448370 )
2018
49
Spatio-temporal cluster and distribution of human brucellosis in Shanxi Province of China between 2011 and 2016. ( 30451894 )
2018
50
Clinical features of 2041 human brucellosis cases in China. ( 30476930 )
2018

Variations for Brucellosis

Expression for Brucellosis

Search GEO for disease gene expression data for Brucellosis.

Pathways for Brucellosis

Pathways related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CD40LG CRP CXCL8 IFNG IL10 IL18
2
Show member pathways
13.88 CD40LG CXCL8 IL10 IL18 IL2 IL2RA
3
Show member pathways
13.77 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
4
Show member pathways
13.62 CXCL8 IFNG IL10 IL18 IL2 IL2RA
5
Show member pathways
13.53 CD40LG CXCL8 IL10 IL18 IL2 IL2RA
6
Show member pathways
13.42 CD40LG CXCL8 IL10 IL18 IL2 IL2RA
7
Show member pathways
13.38 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
8
Show member pathways
13.23 IFNG IL2 IL2RA IL4 TLR4 TNF
9
Show member pathways
13.15 CXCL8 IFNG IL10 IL18 IL2 IL6
10
Show member pathways
13.05 IL2 IL2RA IL4 IL6 TLR4 TNF
11
Show member pathways
12.97 CD40LG CXCL8 IFNG IL10 IL18 IL2
12 12.93 CXCL8 IFNG IL2 IL2RA IL4 IL6
13
Show member pathways
12.92 CXCL8 IFNG IL18 IL2 IL2RA IL4
14
Show member pathways
12.91 CXCL8 IFNG IL18 IL6 SAA1 TLR4
15
Show member pathways
12.82 IL2 IL2RA IL4 IL6 TNF
16
Show member pathways
12.79 CD40LG IFNG IL10 IL18 IL2 IL2RA
17
Show member pathways
12.76 CD40LG IL2 IL6 TLR4 TNF
18
Show member pathways
12.73 IFNG IL10 IL18 IL2 IL6 TNF
19 12.7 CD40LG IFNG IL10 IL1RN IL2 IL2RA
20
Show member pathways
12.67 IFNG IL10 IL18 IL2 IL2RA IL4
21
Show member pathways
12.6 CD40LG IFNG IL10 IL2 IL4 IL6
22
Show member pathways
12.55 IFNG IL10 IL2 IL2RA IL4 IL6
23
Show member pathways
12.53 IFNG IL2 IL4 TNF
24
Show member pathways
12.51 CRP IFNG IL2 IL4 IL6 SAA1
25 12.46 IL2 IL2RA IL6 TNF
26
Show member pathways
12.46 CXCL8 IFNG IL4 IL6 TNF
27
Show member pathways
12.43 CXCL8 IFNG IL6 TLR4 TNF
28
Show member pathways
12.43 CD40LG IFNG IL10 IL4 TLR4 TNF
29 12.4 IFNG IL10 IL18 IL6 TLR4 TNF
30
Show member pathways
12.37 CXCL8 IL18 IL1RN IL6 TNF
31
Show member pathways
12.36 CXCL8 IFNG IL4 IL6 TLR4 TNF
32
Show member pathways
12.33 CXCL8 IL6 TLR4 TNF
33 12.33 CXCL8 IL10 IL1RN IL6 TNF
34
Show member pathways
12.32 CXCL8 IFNG IL10 IL18 IL2 IL2RA
35
Show member pathways
12.28 IL10 IL2 IL6 TNF
36 12.26 IFNG IL6 TLR4 TNF
37
Show member pathways
12.23 CXCL8 IFNG IL10 IL18 IL2 IL2RA
38
Show member pathways
12.22 IFNG IL10 IL18 IL2 IL6 TLR4
39
Show member pathways
12.21 IFNG IL4 IL6 TLR4 TNF
40 12.17 CXCL8 IFNG IL2 IL4 IL6 TLR4
41
Show member pathways
12.15 IFNG IL18 IL2 IL2RA IL4
42 12.13 IFNG IL10 IL2 IL2RA IL4 IL6
43 12.11 CXCL8 IL10 IL18 IL4 IL6 SAA1
44 12.08 CXCL8 IFNG IL10 IL6 TLR4 TNF
45 12.05 IFNG IL10 IL2 IL2RA IL6
46 12.03 CXCL8 IFNG IL18 IL6 TLR4 TNF
47 12.02 IL2RA IL4 IL6 TNF
48 12.02 CXCL8 IFNG IL18 IL6 TLR4
49 12.01 CD40LG CXCL8 TLR4 TNF
50 12 CXCL8 IL18 IL2 TLR4

GO Terms for Brucellosis

Cellular components related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.81 CD40LG CXCL8 IFNG IL1RN IL2 IL2RA
2 extracellular region GO:0005576 9.73 CD40LG CRP CXCL8 IFNG IL10 IL18
3 extracellular space GO:0005615 9.4 CD40LG CRP CXCL8 IFNG IL10 IL18

Biological processes related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.96 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 CD40LG IL18 IL6 TLR4 TNF
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 IL10 IL6 TNF
4 platelet activation GO:0030168 9.92 CD40LG IL6 SAA1
5 positive regulation of gene expression GO:0010628 9.92 CRP IFNG IL18 IL4 IL6 SLC11A1
6 defense response to Gram-positive bacterium GO:0050830 9.91 CRP IL6 TNF
7 cellular response to lipopolysaccharide GO:0071222 9.91 CXCL8 IL10 IL1RN IL6 TLR4 TNF
8 defense response to Gram-negative bacterium GO:0050829 9.89 IL6 SLC11A1 TLR4
9 neutrophil chemotaxis GO:0030593 9.89 CXCL8 IL1RN SAA1
10 positive regulation of JNK cascade GO:0046330 9.89 IL1RN TLR4 TNF
11 positive regulation of inflammatory response GO:0050729 9.89 IL18 IL2 TLR4 TNF
12 negative regulation of inflammatory response GO:0050728 9.89 IL10 IL2 IL2RA MEFV SAA1
13 B cell differentiation GO:0030183 9.88 CD40LG IL10 IL4
14 humoral immune response GO:0006959 9.87 IFNG IL6 TNF
15 response to glucocorticoid GO:0051384 9.87 IL10 IL1RN IL6 TNF
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 IL18 IL6 TNF
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 IL18 TLR4 TNF
18 positive regulation of interleukin-6 production GO:0032755 9.86 IL1RN IL6 TLR4 TNF
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL18 IL2 IL4 IL6
20 cytokine-mediated signaling pathway GO:0019221 9.85 CXCL8 IL10 IL18 IL1RN IL2 IL2RA
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IFNG TLR4 TNF
22 positive regulation of B cell proliferation GO:0030890 9.84 IL2 IL4 TLR4
23 acute-phase response GO:0006953 9.82 CRP IL6 SAA1
24 lipopolysaccharide-mediated signaling pathway GO:0031663 9.82 IL18 TLR4 TNF
25 negative regulation of interleukin-6 production GO:0032715 9.81 IL10 TLR4 TNF
26 positive regulation of cytokine secretion GO:0050715 9.8 IL10 SAA1 TNF
27 positive regulation of T cell proliferation GO:0042102 9.8 CD40LG IL2 IL2RA IL4 IL6
28 positive regulation of activated T cell proliferation GO:0042104 9.79 IL18 IL2 IL2RA
29 positive regulation of interleukin-12 production GO:0032735 9.79 CD40LG IFNG TLR4
30 positive regulation of chemokine production GO:0032722 9.78 IL6 TLR4 TNF
31 positive regulation of T cell differentiation GO:0045582 9.77 IL2 IL2RA IL4
32 positive regulation of interferon-gamma production GO:0032729 9.77 IL18 IL2 SLC11A1 TLR4 TNF
33 immune response GO:0006955 9.77 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
34 regulation of regulatory T cell differentiation GO:0045589 9.76 IFNG IL2 IL2RA
35 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.75 IFNG TNF
36 negative regulation of growth of symbiont in host GO:0044130 9.74 IL10 TNF
37 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL10 TNF
38 positive regulation of interleukin-17 production GO:0032740 9.74 IL18 IL2
39 regulation of protein secretion GO:0050708 9.74 SAA1 TNF
40 interferon-gamma production GO:0032609 9.73 IL18 TLR4
41 negative regulation of interleukin-12 production GO:0032695 9.73 IL10 MEFV
42 negative regulation of interleukin-17 production GO:0032700 9.73 IFNG TLR4
43 positive regulation of immunoglobulin secretion GO:0051024 9.73 IL2 IL6
44 response to molecule of bacterial origin GO:0002237 9.73 CXCL8 IL10
45 interleukin-2-mediated signaling pathway GO:0038110 9.73 IL2 IL2RA
46 macrophage activation GO:0042116 9.72 SLC11A1 TLR4
47 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.72 IL10 IL1RN
48 neutrophil activation GO:0042119 9.72 CXCL8 IL18
49 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
50 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL2 IL4

Molecular functions related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 CD40LG CXCL8 IFNG IL10 IL18 IL1RN
2 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 IL6

Sources for Brucellosis

2